PDE III Inhibitors
1 drugsAbout PDE III
Phosphodiesterase III (PDE III) regulates intracellular levels of cAMP and cGMP by breaking them down. This enzyme influences physiological processes, particularly in cardiovascular and respiratory systems, impacting smooth muscle relaxation and cardiac contractility.
While there is currently no genetic evidence directly linking PDE III to specific diseases, its role in critical pathways makes it a relevant target. Therapeutic interventions modulating PDE III activity have shown promise, especially in respiratory conditions.
PDE III is targeted by one FDA-approved drug, THEO-24, a small molecule approved in 1983 for respiratory indications. ENDO OPERATIONS is the sole company with an approved PDE III-targeting drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Triple-negative Breast Cancer with only 1 trials.
Top PDE III Drugs
ENDO OPERATIONS is the only company with an approved drug targeting PDE III.
The lack of competition suggests high barriers to entry or limited market potential.
PDE III Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDE III, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could create differentiation.
PDE III Clinical Trials 38 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 5 | 2 | 1 | 71% |
| Phase 2 | 14 | 10 | 0 | 3 | 100% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 13 | 11 | 1 | 1 | 92% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
PDE III Drug Approval Timeline (1983 - 1983)
THEO-24 was the first and only drug approved in 1983, representing the entire approval history.
The absence of recent approvals indicates a saturated market or challenges in developing new PDE III modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 24 clinical trials targeting PDE III.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities